Session » Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1726

A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE

8:30AM-10:30AM: Abstract Number: 1721

A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 1712

Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants

8:30AM-10:30AM: Abstract Number: 1727

Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes

8:30AM-10:30AM: Abstract Number: 1720

Cervical Dysplasia and HPV Infection in Women with Vasculitis

8:30AM-10:30AM: Abstract Number: 1731

Construction and Validation of a Reproductive Health Questionnaire for Women with Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 1730

Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS

8:30AM-10:30AM: Abstract Number: 1714

Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 1723

Factors Associated with Postpartum Flare in Women with Lupus

8:30AM-10:30AM: Abstract Number: 1725

Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results

8:30AM-10:30AM: Abstract Number: 1711

Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results

8:30AM-10:30AM: Abstract Number: 1724

More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database

8:30AM-10:30AM: Abstract Number: 1717

One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center

8:30AM-10:30AM: Abstract Number: 1719

Pandemic-Associated Complications in Pregnant Women with Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 1729

Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)

8:30AM-10:30AM: Abstract Number: 1715

Providing High Quality Family Care Planning for Women with Rheumatic Disease in Rheumatology Clinics: Perspectives of Rheumatology Clinicians

8:30AM-10:30AM: Abstract Number: 1722

Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark

8:30AM-10:30AM: Abstract Number: 1713

Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab

8:30AM-10:30AM: Abstract Number: 1728

Takayasu’s Arteritis and Pregnancy: A Meta-analysis

8:30AM-10:30AM: Abstract Number: 1716

Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center

8:30AM-10:30AM: Abstract Number: 1718

Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].